EZH2 and breast carcinoma: Furthermore, we show that breast cancer expressing both higher EZH2 and lower CDKN1C show a much poorer disease-free survival rate (P = 0.001046) compared to patients with lower EZH2 and higher CDKN1C (Figure 6C).